Navid Djassemi MD M.S.
Bone Marrow Transplant/Cellular Therapy Fellow at Children's National Hospital/National Institute of Health
Join to View Full Profile
111 Michigan Ave NWWashington, DC 20010
Dr. Djassemi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- HSCT, Adoptive Cell Therapy, Immunotherapy, Cancer Genetics/Cancer Risk Assessment, Inherited Bone Marrow Failure Syndromes, Clinical Informatics
Education & Training
University of California (San Diego) Medical CenterFellowship, Pediatric Hematology/Oncology, 2021 - 2024
Hackensack University Medical CenterResidency, Pediatrics, 2019 - 2021- Hackensack University Medical CenterInternship, Pediatrics, 2018 - 2019
Ross University School of MedicineClass of 2017, MD
California Polytechnic State UniversityMS, Biomedical Engineering, 2009 - 2010- California Polytechnic State UniversityBS, Biomedical Engineering, 2004 - 2010
Publications & Presentations
PubMed
- Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis.Justine Perrin, Karim Farid, Hilde Van Parijs, Olena Gorobets, Vincent Vinh-Hung
World Journal of Clinical Oncology. 2022-04-24 - 3 citationsExamining the evolving utility of 18 FDG-PET/CT in breast cancer recurrenceNavid Djassemi, Shilpa Rampey, Juhi Motiani
Translational Cancer Research. 2020-01-01 - 3 citationsPreoperative [18]fluorodeoxyglucose-positron emission tomography/computed tomography in early stage breast cancer: Rates of distant metastases.Vincent Vinh-Hung, Hendrik Everaert, Karim Farid, Navid Djassemi, Jacqueline Baudin-Veronique
World Journal of Radiology. 2017-07-28
Journal Articles
- Short-Term Outcomes From Pulmonary Rehabilitation In An Adolescent Patient With EVALIDjassemi, N., Zertuche, J.P., Liebling, M., Siegel, M., Lee, A., Authorea, 9/20
- Day 8 Minimal Residual Disease of 67% in a Child with Standard Risk B-Lymphoblastic LeukemiaNavid Djassemi, MD, Burton Appel MD, MBA, Pediatric Blood and Cancer, 4/2020
- Examining The Evolving Utility of [18]FDG-PET/CT In Breast Cancer RecurrenceNavid Djassemi, MD, Shilpa Rampey, MD, Juhi Motiani MD, Translation Cancer Research (Radiotherapy for Breast Cancer in Advanced Age), 1/2020
- Join now to see all
Abstracts/Posters
- Thrombocytopenia And Eczema Due To A Novel RUNXI MutationNavid Djassemi, MD, Sioban Keel, MD, Jessica Mandell, MS, CGC, David Wu, MD, PhD, Silvia Casadei, PhD, Tomas Walsh, PhD, Mary-Claire King, PhD, Akiko Shimamura, MD,..., American Society of Pediatric Hematology Oncology, New Orleans, LA, 5/2019
Research History
- Tissue Engineering Researcher2009 - 2011
Professional Memberships
- American Academy of PediatricsMember
- Member
- American Society of Pediatric Hematology OncologyMember
Other Languages
- Spanish, Farsi
External Links
- LinkedInhttps://www.linkedin.com/in/navid-djassemi-0579b520/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
